Valo Therapeutics appoints Hemanshu Shah as Chief Business Officer
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas
The company has 47 ANDA's pending approval with the U.S.FDA
Subscribe To Our Newsletter & Stay Updated